Interview with Rhenu Bhuller, Vice President of Health Care for Asia Pacific,…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Address: 100 Beach Road
#29-01/11, Shaw Tower
Singapore 189 702
Tel: +65 68900999
Web: http://www.frost.com/c/10024/home.do
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.
Through Frost & Sullivan’s Healthcare Growth Partnership Services program, clients receive a continuous flow of actionable market, technical, and econometric research, along with applications for growth. They continuously monitor the following Healthcare market sectors: pharmaceuticals and biotechnology, drug discovery technologies, clinical diagnostics, healthcare IT, medical imaging, and medical devices, and provides local expertise along with a global perspective.
Consultant
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical…
Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs…
The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures, infrastructures, and economic development. Managing a…
Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the…
Professor Subra Suresh, president of Nanyang Technological University (NTU) and former director of the US National Science Foundation, explains how the university has managed to consistently be among the top…
Marco Lee, APAC head for medical device firm Avanos explains how the company’s products are catered to patient needs in the region and talks through key growth drivers, the impact…
AstraZeneca (AZ)’s country president for Singapore, Vinod Narayanan, outlines the challenges of taking the reins at an affiliate against the backdrop of a pandemic and how the Anglo-Swedish company’s quest…
One of the main supporting pillars of Singapore’s pharmaceutical industry is its magnificent manufacturing base. Not only does the city-state rank as one of the few countries on the planet…
Cindy Engelbart, director of mid-sized logistics player Agility’s life science operations in APAC, highlights some of the key trends in global logistics that have emerged from the COVID-19 pandemic, how…
In 2020, the FDA granted its first approval to a comprehensive liquid biopsy, potentially representing a paradigm shift towards using liquid biopsies upfront as an easier, safer, faster, and more…
See our Cookie Privacy Policy Here